Coleus (Makandi) for Blood Pressure Regulation

Research suggests that Coleus forskohlii, and its primary active compound forskolin, may support blood pressure reduction through vasodilatory mechanisms, with evidence drawn from a direct clinical trial in hypertensive geriatric patients showing significant reductions in blood pressure, an animal study demonstrating dose-dependent decreases in mean arterial pressure, and a cardiovascular study in heart disease patients confirming forskolin's vasodilatory effects at lower doses. Studies indicate that the blood pressure-related activity is linked to forskolin's ability to activate cellular signaling pathways that relax blood vessel walls, reducing vascular resistance. The available body of evidence is generally supportive in direction but limited in scope, relying heavily on a single human clinical trial, one animal model, older cardiovascular research, and several descriptive or review-level sources rather than a robust series of large randomized controlled trials. As such, while the preliminary findings are promising and consistent with a plausible biological mechanism, the evidence base remains modest, and broader and more rigorous human trials would be needed to draw firm conclusions about the herb's role in blood pressure management.